Erratum: Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I) (Modern Rheumatology, 10.3109/14397595.2013.854059);Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)

Modern Rheumatology

Volumn 24, Issue 1, 2014, Pages 33-40

  Yamanaka, Hisashi ^a   Sugiyama, Naonobu ^b   Inoue, Eisuke ^a   Taniguchi, Atsuo ^a   Momohara, Shigeki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b PFIZER INC   (United States)

Author keywords

Database; Epidemiology; Health insurance; Prevalence; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ACTARIT; ADALIMUMAB; AURANOFIN; AUROTHIOMALATE; BUCILLAMINE; CORTICOSTEROID; INFLIXIMAB; LEFLUNOMIDE; LOBENZARIT; METHOTREXATE; MIZORIBINE; PENICILLAMINE; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; FEMALE; HUMAN; ICD-10; INTERNATIONAL CLASSIFICATION OF DISEASES; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; FEMALE; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; JAPAN; METHOTREXATE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 84896906847     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.866357     Document Type: Erratum

References (31)

1. Yamanaka H, Seto Y, Tanaka E, Furuya T, Nakajima A, Ikari K, et al. Management of rheumatoid arthritis: the 2012 perspective. Mod Rheumatol. 2012. doi:10.1007/s10165-012-0702-1.
2. Seto Y, Tanaka E, Inoue E, Nakajima A, Taniguchi A, Momohara S, et al. Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database. Mod Rheumatol. 2011;21:579-93. doi:10.1007/s10165-011-0445-4.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64: 625-39. doi:10.1002/acr.21641.
4. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75. doi:10.1136/ard.2009.126532.
5. Imanaka T, Shichikawa K, Inoue K, Shimaoka Y, Takenaka Y, Wakitani S. Increase in age at onset of rheumatoid arthritis in Japan over a 30-year period. Ann Rheum Dis. 1997;56:313-6.
6. Shichikawa K, Inoue K, Hirota S, Maeda A, Ota H, Kimura M, et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis. 1999;58:751-6.
7. Watanabe K, Urata S, Suzuki K, Ohba M, Inagaki Y. Progressive and nonprogressive rheumatoid arthritis over a 10-year period in Japan. J Rheumatol Suppl. 2004;69:27-9.
8. Momohara S, Inoue E, Ikari K, Yano K, Tokita A, Honjo Y, et al. Comparison of characteristics and therapeutic efficacy in rheumatoid arthritis patients treated by rheumatologists and those treated by orthopedic surgeons under a team medicine approach at the same institute. Mod Rheumatol. 2012;22:209-15. doi: 10.1007/s10165-011-0495-7.
9. Nakajima A, Inoue E, Shidara K, Hoshi D, Sato E, Seto Y, et al. Standard treatment in daily clinical practice for early rheumatoid arthritis improved disease activity from 2001 to 2006. Mod Rheumatol. 2011;21:594-7. doi:10.1007/s10165-011-0457-0.
10. Yamanaka H. A cohort study of clinical care in rheumatoid arthritis: the IORRA study. JMAJ. 2009;52:54-6.
11. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17:283-9. doi:10.1007/s10165-007-0587-6.
12. Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413-9.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
14. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf. 2010;19:256-65. doi:10.1002/pds.1912.
15. Smeets HM, de Wit NJ, Hoes AW. Routine health insurance data for scientific research: potential and limitations of the Agis Health Database. J Clin Epidemiol. 2011;64:424-30. doi: 10.1016/j.jclinepi.2010.04.023.
16. Garrison LP Jr., Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007;10:326-35. doi:10.1111/j.1524-4733.2007. 00186.x.
17. Bernard MA, Benichou J, Blin P, Weill A, Begaud B, Abouelfath A, et al. Use of health insurance claim patterns to identify patients using nonsteroidal anti-inflammatory drugs for rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2012;. doi:10.1002/pds.3221.
18. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken). 2011;63:1680-90. doi:10.1002/acr.20629.
19. McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis. J Rheumatol. 2011;38:2141-9. doi:10.3899/jrheum.101195.
20. Petri H, Maldonato D, Robinson NJ. Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskelet Disord. 2010; 11:247. doi:10.1186/1471-2474- 11-247.
21. Thayer S, Watson C, Song R, Globe DR, Harrison DJ. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13:228-35. doi:10.3111/13696998.2010.487469.
22. Wong BJ, Cifaldi MA, Roy S, Skonieczny DC, Stavrakas S. Analysis of drug and administrative costs allowed by US private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis. J Manag Care Pharm. 2011;17:313-20.
23. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care. 2003;9:S136-43.
24. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9,074 patients with rheumatoid arthritis. J Rheumatol. 2009; 36:907-13. doi:10.3899/jrheum.080592.
25. Kirigaya D, Nakayama T, Ishizaki T, Ikeda S, Satoh T. Management and treatment of osteoporosis in patients receiving long-term glucocorticoid treatment: current status of adherence to clinical guidelines and related factors. Intern Med. 2011;50: 2793-800.
26. Nakaoka S, Ishizaki T, Urushihara H, Satoh T, Ikeda S, Morikawa K, et al. Echocardiography for the detection of valvulopathy associated with the use of ergot-derived dopamine agonists in patients with Parkinson's disease. Intern Med. 2011;50:687-94.
27. Ministry of Health, Labour and Welfare. Results of the 2008 patient survey: Total number of patients with severe disease. http://www.mhlw.go.jp/ toukei/saikin/hw/kanja/08/dl/05.pdf (In Japanese). Last Accessed 10 August 2012.
28. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36:182-8. doi:10.1016/j.semarthrit.2006.08.006.
29. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7. doi:10.1136/ard.2009. 123919.
30. Gayet-Ageron A, Agoritsas T, Schiesari L, Kolly V, Perneger TV. Barriers to participation in a patient satisfaction survey: who are we missinǧ PLoS ONE. 2011;6:e26852. doi:10.1371/journal. pone.0026852.
31. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40:IV-26-35. doi:10.1097/01.mlr.0000020936. 03651.2d.